IRE ELiT, IRE’s innovation subsidiary, was founded in 2010 to develop radiopharmaceuticals used for imaging and treatment of certain cancers and palliative care.
IRE-Elit produces Galli Ad and Galli Eo, the pharmaceutical grade Ge-68/Ga-68 generators.
Activities and description
In order to get closer to patients and strengthen its international role as a major player in the field of nuclear medicine, IRE – IRE ELiT has diversified its activities in the production of radiopharmaceutical products.
Their portfolio of customer-oriented solutions consists of radioisotopes as well as equipment dedicated to their preparation.
Nuclear medicine departments and research centres.